The Cost of Calm
Stress, anger, and anxiety do not only fray lives, they cost the global economy on a colossal scale.
Yet we rarely count those losses. A device such as Calmate would not solve everything, but its economic benefits would be immense. Globally, the consequences of anger are estimated to cost $190 billion each year in loss of productivity and medical expenses.
Or consider work-related stress. We can estimate the global cost to be a staggering $922 billion every year. This amount is based on the reported $187 billion (2018) for the US, which has been adjusted for inflation and scaled using GDP to produce a worldwide estimate. Because the bulk of stress-related losses arise from absenteeism, presenteeism, and healthcare strain, which scale with economic activity rather than population size, a GDP-proportional extrapolation yields a reasonable lower bound. That is in line with a study from the Nordics that places the cost of work-related stress at a few percent of GDP. If we pick a conservative 1% of GDP as the cost of stress across all nations, we already exceed $1 trillion.
The picture grows darker when we add anxiety. Anxiety and depression cost the global economy more than $1 trillion and potentially as much as $6.5 trillion, with projections of $16 trillion by 2030. The lower bound reflects distinct, non-overlapping categories, whereas the upper bound captures the broader cluster of disorders where boundaries blur. While there is certainly some overlap between stress, anxiety, and anger, we can estimate the annual economic cost of stress, anger, and anxiety to be between $1 trillion and $6.7 trillion, or up to 6% of global GDP. For comparison, that is more than global e-commerce sales, roughly the size of the market for wellness, and larger than the economies of the United Kingdom and France combined. It is even larger than projections for the entire market for AI in about eight years’ time.
Compared to those losses, the markets for treatment are tiny:
- $20 billion for stress management
- $12 billion for anxiety disorders
- $9 billion for cognitive behavioural therapy
- $6.5 billion for mental health apps
- $4.3 billion for mental health tracking devices
- $2.5 billion for online anger management classes
Market opportunity and the argument for affordability
To make the world a better place by reducing stress, anxiety, and anger across populations, Calmate must be globally affordable. A luxury device that few can afford does not benefit society.
Fortunately, we can construct a prototype of Calmate with about $20 of ethically sourced materials. The components (thermoelectric coolers, low-power microcontrollers, commodity PPG sensors) already appear in mass-market electronics, which keeps the bill of materials manageable. A model sold for $25 would be affordable for most adults in middle- and high-income countries, because median monthly wages for low-, middle-, and high-income countries are $201, $630, and $3,333, respectively. This price point is under one-tenth of that of (refurbished) smartphones.
How large could the market for Calmate be? Assuming 65% of the world’s population are adults, we can estimate there to be 406 million, 3.84 billion, and 923 million adults in each group. The global market is therefore almost 4.8 billion adults. If Calmate must occasionally sync with a smartphone, the upper bound is the number of adults who own one (68%), or 3.6 billion people. That upper bound is plausible, since roughly 23% of adults globally already own wearables. Let’s pick 4 billion. Even at an average price of $25, the potential market approaches $100 billion.
In a generous scenario where Calmate achieves widespread adoption, potentially up to three quarters of the adult population, which is on par with global smartphone ownership, annual savings of about $5 trillion would imply societal returns of fifty to one. But even a reduction of a few percent in global losses would outweigh manufacturing costs by an order of magnitude.
Why not offer a $299 device and profit much more? Because too many products cater to the affluent without really adding anything valuable to society. Just think about all the apps that offer infinite (doom)scrolling designed to turn everyone's smartphone into a billboard to make consumers buy more stuff they do not really need, simply because the tech companies can and because it makes their shareholders wealthier. Few think about whether that makes any sense, because they lack the moral ambition. A product that addresses stress, anger, and anxiety, should not be a device of privilege but built by a public benefit corporation. That way, the many can benefit rather than merely the few.
What is more, mental health disorders are more prevalent among the poor. These drive short-sighted, risk-averse choices that make it harder to escape poverty, which in turn amplifies psychological distress. The worst economic conditions are systematically concentrated among those with the worst mental health. So, any relief for stress, anger, or anxiety that is not affordable skips the group that stands to benefit the most.
The financial opportunity and potential societal impact for Calmate are enormous. And because the greatest burdens fall on those with the fewest resources, affordability is not merely an economic concern but an ethical obligation.